Organon & Co | OGN - Current Liabilities


Organon & Co reported $2.68B in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Celltrion KRW 4.01T 343.96B Sep/2025
Cspc Pharmaceutical CNY 10.18B 65.36M Dec/2025
Deva Holding AS TRY 6.43B 1.18B Sep/2023
Dianthus Therapeutics USD 30.73M 6.88M Dec/2025
Divis Laboratories Ltd INR 17.28B 2.76B Sep/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Kangmei Pharma CNY 5.81B 57.93M Sep/2025
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Laboratorios Farma EUR 199.84M 121.75M Dec/2023
Malin Corporation EUR 1000K 500K Dec/2024
Medical Developments International AUD 5.56M 2.26M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Neuren Pharmaceuticals AUD 4.34M 3.58M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Organigram Holdings CAD 94.05M 32.11M Dec/2025
Organon & Co USD 2.68B 117M Sep/2025
Ovoca Bio EUR 186K 2.26M Jun/2025
Pharma Mar EUR 93.88M 4.94M Dec/2025
Qiagen NV USD 512.14M 461.26M Dec/2025
Sartorius EUR 1.81B 254.3M Sep/2025
Sino Biopharmaceutical CNY 24.85B 5.29B Jun/2025
Tilray USD 259.32M 8.32M Sep/2025
Zealand Pharma A/S 664.96M 513.61M Dec/2025